Challenge-mig: a phase 4, randomized, double-blind, double-dummy study comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine
Journal of the Neurological Sciences（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要